公开(公告)号：EP1962605A2

公开(公告)日：2008-09-03

申请号：EP06839263.8

申请日：2006-12-08

申请人： Merck & Co., Inc.

发明人： SAMUEL, Rachel, G. ,  SANTINI, Conrad

IPC分类号： A01N43/78 ,  A61K31/425

CPC分类号： C07D417/14 ,  C07D471/04

摘要： The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

公开(公告)号：EP1194146A1

公开(公告)日：2002-04-10

申请号：EP00944694.9

申请日：2000-06-16

申请人： Merck & Co., Inc.

发明人： SAHOO, Soumya, P. ,  SANTINI, Conrad ,  BOUERES, Julia, K. ,  HECK, James, V. ,  METZGER, Edward ,  LOMBARDO, Victoria, K.

IPC分类号： A61K31/421 ,  A61K31/427 ,  A61K31/497 ,  C07D241/12 ,  C07D241/14 ,  C07D263/04 ,  C07D277/04

CPC分类号： C07D277/34 ,  C07D417/12

摘要： Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or η mediated diseases, disorders and conditions.